Standard BioTools Stock

Standard BioTools Financing Cash Flow

The Net Financing Cash Flow of Standard BioTools (LAB) as of Aug 13, 2026 is 570,000.00 USD. In the previous year, Net Financing Cash Flow was -102.62 M USD — a change of -100.56% (higher).

Financing Cash Flow

570,000.00USD

YoY

-100.56%

Last updated:

Net Financing Cash Flow of Standard BioTools is 2026 570,000.00 USD. Net Financing Cash Flow of Standard BioTools was 2025 -102.62 M USD. It decreases by -100.56% higher compared to the previous year.
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Net Financing Cash Flow of Standard BioTools is 570,000.00 USD in 2026.

Net Financing Cash Flow of Standard BioTools changed from -102.62 M USD to 570,000.00 USD, representing a -100.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Standard BioTools

All Key Metrics — Standard BioTools